Table 3.

(A) Percent of melanoma tissues exhibiting methylation of TRGs and MINT loci
AJCC stage (n)	MINT17	MINT31	WIF1	TFPI2	RASSF1A	RARβ2	SOCS1	GATA4
I, P (18)	11.1	5.6	5.6	0	0	58.3	7.1	16.7
II, P (17)	17.6	23.5	6.3	6.3	0	66.7	23.1	8.3
III, P (17)	41.2	35.3	31.3	17.6	26.7	64.3	25	42.9
III, M (18)	52.9	27.8	50	17.6	27.8	47.1	23.5	22.2
IV, M (52)	38.5	36.5	44	44.9	48.9	56.3	44.9	34
Overall (122)	34.2	28.1	33.3	21.7	28.6	57.6	31.5	27.5
(B) Difference in methylation status between AJCC stages
Stage comparison	MINT17	MINT31	WIF1	TFPI2	RASSF1A	RARβ2	SOCS1	GATA4
Stage I vs II	NS	NS	NS	NS	NS	NS	NS	NS
Stage I vs III	0.049	0.036	NS	NS	NS	NS	NS	NS
Stage I vs IV*	0.021	0.005	0.003	0.006	<0.0001	NS	0.005	NS
Stage II vs III	NS	NS	NS	NS	0.015	NS	NS	0.039
Stage II vs IV*	NS	NS	0.015	0.013	<0.0001	NS	NS	0.055
Stage III vs IV*	NS	NS	NS	NS	NS	NS	NS	NS

NOTE: Bold entries refers to ≥50%. P value analyzed by Fisher's exact test. NS, not significant. P values < 0.0083 are significant after Bonferroni correction (in bold).

Abbreviations: P, primary; M, metastatic. For additional information on specimen, see Table 1.

^*For comparisons with stage IV, χ² test was used.